Bioinformatics analysis reveals connection of squamous cell carcinoma and adenocarcinoma of the lung

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1477-1482

  Fan, Wei Dong ^a   Zhang, Xian Quan ^a   Guo, Hui Lin ^a   Zeng, Wei Wei ^a   Zhang, Ni ^a   Wan, Qian Qian ^a   Xie, Wen Yao ^a   Cao, Jin ^a   Xu, Chang Hua ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Adenocarcinoma; Lung cancer; Regulatory network; Squamous cell carcinoma

Indexed keywords

TRANSCRIPTION FACTOR;

ADENOCARCINOMA; ARTICLE; DNA MICROARRAY; GENE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETICS; HUMAN; LUNG TUMOR; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; GENES; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTION FACTORS;

EID: 84873042441     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1477     Document Type: Article

References (42)

1. Beattie CW, Hansen NW, Thomas PA (1985). Steroid receptors in human lung cancer. Cancer Res, 45, 4206-14.
2. Beer DG, Kardia SL, Huang CC, et al (2002). Geneexpression profiles predict survival of patients with lung adenocarcinoma. Nat Med, 8, 816-24.
3. Bhattacharjee A, Richards WG, Staunton J, et al (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A, 98, 13790-5.
4. Bodner SM, Minna JD, Jensen SM, et al (1992). Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene, 7, 743-9.
5. Brivanlou AH, Darnell JE, Jr (2002). Signal transduction and the control of gene expression. Science, 295, 813-8.
6. Colon J, Basha MR, Madero-Visbal R, et al (2011). Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs, 29, 41-51.
7. Ding L, Getz G, Wheeler DA, et al (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 455, 1069-75.
8. Dreesen O, Brivanlou AH (2007). Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev, 3, 7-17.
9. Ermolaeva O, Rastogi M, Pruitt KD, et al (1998). Data management and analysis for gene expression arrays. Nat Genet, 20, 19-23.
10. Fromm M, Littman P, Raney RB, et al (1986). Late effects after treatment of twenty children with soft tissue sarcomas of the head and neck. Experience at a single institution with a review of the literature. Cancer, 57, 2070-6.
11. Garber ME, Troyanskaya OG, Schluens K, et al (2001). Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A, 98, 13784-9.
12. Gemma A, Nakajima T, Shiraishi M, et al (1988). myc family gene abnormality in lung cancers and its relation to xenotransplantability. Cancer Res, 48, 6025-8.
13. Huang da W, Sherman BT, Lempicki RA (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 4, 44-57.
14. Ji H, Wang Z, Perera SA, et al (2007). Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res, 67, 4933-9.
15. Jiang C, Xuan Z, Zhao F, Zhang MQ (2007). TRED: a transcriptional regulatory element database, new entries and other development. Nucleic Acids Res, 35, D137-40
16. Johnson BE, Ihde DC, Makuch RW, et al (1987). myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest, 79, 1629-34.
17. Joseph D, Lolita P, Patrick OB, et al (1996). Use of a cDNA microarry to analyse gene expression patterns in human cancer. Nature Genetics, 14, 457-60.
18. Kanehisa M (2002). The KEGG database. Novartis Found Symp, 247, 91-101 (discussion 101-3, 119-28, 244-52).
19. Khan J, Simon R, Bittner M, et al (1998). Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res, 58, 5009-13.
20. Kosaka T, Yatabe Y, Onozato R, et al (2009). Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol, 4, 22-9.
21. Le Calvez F, Mukeria A, Hunt JD, et al (2005). TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res, 65, 5076-83.
22. Li R, Wang H, Bekele BN, et al (2006). Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene, 25, 2628-35.
23. Marquez-Garban DC, Chen HW, Fishbein MC, et al (2007). Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids, 72, 135-43.
24. Martin O, Karl-heinz H, Hartmut B (1998). TGF-beta signaling is necessary for carcinoma cell invasiveness and metastasis. Current Biology, 8, 1243-52.
25. Miura K, Bowman ED, Simon R, et al (2002). Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosisrelated molecular profiles. Cancer Res, 62, 3244-50.
26. Nakanishi H, Matsumoto S, Iwakawa R, et al (2009). Whole genome comparison of allelic imbalance between noninvasive and invasive small-sized lung adenocarcinomas. Cancer Res, 69, 1615-23.
27. Philipsen S, Suske G (1999). A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucleic Acids Res, 27, 2991-3000.
28. Qu P, Roberts J, Li Y, et al (2009). Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. Lung Cancer, 63, 341-7.
29. Ramaswamy S, Ross KN, Lander ES and Golub TR, (2003). A molecular signature of metastasis in primary solid tumors. Nat Genet, 33, 49-54.
30. Rodenhuis S, Slebos RJ, Boot AJ, et al (1988). Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res, 48, 5738-41.
31. Rodenhuis S, van de Wetering ML, Mooi WJ, et al (1987). Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med, 317, 929-35.
32. Schena M, Shalon D, Davis RW, Brown PO (1995).Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science, 270, 467-70.
33. Sekido Y, Fong KM, Minna JD (1998). Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta, 1378, F21-59.
34. Shannon P, Markiel A, Ozier O, et al (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 13, 2498-504.
35. Subramanian J, Govindan R (2007). Lung cancer in never smokers: a review. J Clin Oncol, 25, 561-70.
36. Takahashi T, Nau MM, Chiba I, et al (1989). p53: a frequent target for genetic abnormalities in lung cancer. Science, 246, 491-4
37. Toyooka S, Tsuda T, Gazdar AF (2003). The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat, 21, 229-39.
38. Travis WD (2002). Pathology of lung cancer. Clin Chest Med, 23, 65-81.
39. Wachi S, Yoneda K, Wu R (2005).I nteractome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics, 21, 4205-8.
40. Wingender E (2008). The TRANSFAC project as an example of framework technology that supports the analysis of genomic regulation. Brief Bioinformatics, 9, 326-32.
41. Yildiz O, Buyuktas D, Ekiz E, et al (2011). Facial nerve palsy: an unusual presenting feature of small cell lung cancer. Case Rep Oncol, 4, 35-8.
42. Zhu WG, Srinivasan K, Dai Z, et al (2003). Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol, 23, 4056-65.